Effects of ruxolitinib cream in patients with atopic dermatitis with baseline body surface area ≥10% and Eczema Area and Severity Index score ≥16: Pooled results from two phase 3 studies

被引：0
|
作者：
Simpson, Eric L. [1 ]
Kircik, Leon [2 ]
Blauvelt, Andrew [3 ]
Kuligowski, Michael E. [4 ]
Venturanza, May E. [4 ]
Sun, Kang [4 ]
Eichenfield, Lawrence F. [5 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Oregon Med Res Ctr, Tigard, OR USA
[4] Incyte Corp, Wilmington, DE USA
[5] Univ Calif San Diego, San Diego, CA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27620
引用
收藏
页码：AB157 / AB157
页数：1
相关论文
共 50 条
  • [41] Evaluating the severity of atopic dermatitis in children and adults: mapping of Investigator's Static Global Assessment to Eczema Area and Severity Index in phase III studies of crisaborole 2%
    Thyssen, J. P.
    Zang, C.
    Neary, M. P.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Cha, A.
    Russo, C.
    Luger, T.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E60 - E60
  • [42] SUBGROUP ANALYSIS OF QUALITY OF LIFE AND TREATMENT SATISFACTION BY BASELINE PATIENT CHARACTERISTICS: POOLED RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES OF RUXOLITINIB CREAM FOR THE TREATMENT OF VITILIGO
    Pandya, A. G.
    van Geel, N.
    Butler, K.
    Bibeau, K.
    Gao, J.
    Ezzedine, K.
    VALUE IN HEALTH, 2022, 25 (07) : S321 - S322
  • [43] EVALUATING THE SEVERITY OF ATOPIC DERMATITIS (AD) IN CHILDREN AND ADULTS: MAPPING OF INVESTIGATOR'S STATIC GLOBAL ASSESSMENT (ISGA) TO ECZEMA AREA AND SEVERITY INDEX (EASI) IN PHASE 3 STUDIES OF CRISABOROLE, 2%
    Thyssen, J. P.
    Zang, C.
    Neary, M. P.
    Bushmakin, A. G.
    Cappelleri, J.
    Cha, A.
    Russo, C.
    Luger, T.
    VALUE IN HEALTH, 2020, 23 : S520 - S520
  • [44] Response to Papp et al's "Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies"
    Isaq, Nasro A.
    Link, Jenny L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (01) : e19 - e20
  • [45] Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score 24 or 24
    Offidani, Annamaria
    Stingeni, Luca
    Neri, Iria
    Cipriani, Filippo
    Chen, Zhen
    Rossi, Ana B.
    Lu, Yufang
    Moretti, Devis
    ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2022, 157 (01) : 39 - 46
  • [46] Ruxolitinib cream provided progressive improvement in patients with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success at week 8: Pooled results from 2 phase 3 studies
    Eichenfield, Lawrence F.
    Blauvelt, Andrew
    Kircik, Leon
    Venturanza, May E.
    Ren, Haobo
    Simpson, Eric L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB202 - AB202
  • [47] Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area
    Gold, Linda Stein
    Bagel, Jerry
    Del Rosso, James
    Green, Lawrence J.
    Lebwohl, Mark
    Kircik, Leon H.
    Feng, Amy
    Snyder, Scott
    Higham, Robert C.
    Burnett, Patrick
    Berk, David R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB192 - AB192
  • [48] Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial
    Yosipovitch, Gil
    Bieber, Thomas
    Gold, Linda Stein
    Kwatra, Shawn
    Tatulych, Svitlana
    Nduaka, Chudy
    Cameron, Michael C.
    Williams, David
    Biswas, Pinaki
    Valdez, Hernan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB41 - AB41
  • [49] Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials
    Simpson, E. L.
    Rahawi, K.
    Hu, X.
    Chu, A. D.
    Nduaka, C.
    Jazayeri, S.
    Lio, P.
    Lynde, C.
    Schuttelaar, M. L. A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, : 1863 - 1870
  • [50] Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: Pooled subgroup analysis from two randomized phase 3 studies
    Rosmarin, David
    Ezzedine, Khaled
    Desai, Seemal R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB50 - AB50
12345